Published in Gut on March 14, 2013
Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab (2013) 1.45
Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides. Proc Natl Acad Sci U S A (2014) 0.95
Transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH. J Lipid Res (2014) 0.88
Fatty acid elongation in non-alcoholic steatohepatitis and hepatocellular carcinoma. Int J Mol Sci (2014) 0.86
Omega-3 polyunsaturated fatty acids as an angelus custos to rescue patients from NSAID-induced gastroduodenal damage. J Gastroenterol (2015) 0.83
A protective lipidomic biosignature associated with a balanced omega-6/omega-3 ratio in fat-1 transgenic mice. PLoS One (2014) 0.81
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Fatty acid desaturase 1 knockout mice are lean with improved glycemic control and decreased development of atheromatous plaque. Diabetes Metab Syndr Obes (2016) 0.80
Activation of hepatic stellate cell in Pten null liver injury model. Fibrogenesis Tissue Repair (2016) 0.80
Reduced dietary omega-6 to omega-3 fatty acid ratio and 12/15-lipoxygenase deficiency are protective against chronic high fat diet-induced steatohepatitis. PLoS One (2014) 0.80
Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Sci Rep (2015) 0.79
The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation. Genes Dev (2016) 0.78
Induction of the hepatic stearoyl-CoA desaturase 1 gene in offspring after isocaloric administration of high fat sucrose diet during gestation. J Clin Biochem Nutr (2013) 0.78
Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades. Sci Rep (2016) 0.77
Novel hepatic microRNAs upregulated in human nonalcoholic fatty liver disease. Physiol Rep (2016) 0.77
Transcriptional networks implicated in human nonalcoholic fatty liver disease. Mol Genet Genomics (2015) 0.77
LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Sci Rep (2016) 0.76
Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Sci Rep (2016) 0.76
Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight (2016) 0.76
A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice. PLoS One (2016) 0.75
Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients. Sci Rep (2017) 0.75
Dietary oleic acid regulates hepatic lipogenesis through a liver X receptor-dependent signaling. PLoS One (2017) 0.75
Alternative RNA Splicing in the Pathogenesis of Liver Disease. Front Endocrinol (Lausanne) (2017) 0.75
Alternation of plasma fatty acids composition and desaturase activities in children with liver steatosis. PLoS One (2017) 0.75
Label-free biomedical imaging with high sensitivity by stimulated Raman scattering microscopy. Science (2008) 10.19
The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg (2008) 5.94
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology (2003) 3.66
Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology (2003) 3.51
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest (2012) 3.45
Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. Hepatology (2010) 3.45
A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology (2004) 3.42
Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation (2003) 3.42
Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology (2007) 3.19
Generation of cloned transgenic pigs rich in omega-3 fatty acids. Nat Biotechnol (2006) 3.07
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 2.83
Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest (2008) 2.73
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci U S A (2006) 2.31
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology (2005) 2.29
Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int (2010) 2.28
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology (2010) 2.22
Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol (2012) 2.20
MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut (2007) 2.09
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology (2012) 2.03
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol (2009) 1.96
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol (2011) 1.87
Hepatorenal syndrome. Lancet (2003) 1.86
Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arterioscler Thromb Vasc Biol (2010) 1.85
Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology (2006) 1.85
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol (2012) 1.81
Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J (2011) 1.79
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology (2005) 1.77
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology (2007) 1.73
Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem (2013) 1.68
Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis (2013) 1.67
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Production of fat-1 transgenic rats using a post-natal female germline stem cell line. Mol Hum Reprod (2013) 1.66
Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology (2011) 1.65
Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology (2006) 1.64
Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty acid desaturase) transgenic mice. Cancer Res (2008) 1.63
Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology (2010) 1.61
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol (2013) 1.61
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. J Urol (2009) 1.59
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Characterization of γδ T cell subsets in organ transplantation. Transpl Int (2010) 1.57
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation (2005) 1.56
Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology (2004) 1.56
Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J Hepatol (2013) 1.55
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology (2006) 1.54
Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut (2012) 1.53
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology (2005) 1.53
Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol (2011) 1.52
Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut (2012) 1.51
Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J (2006) 1.50
Prognostic value of microRNA expression pattern in upper tract urothelial carcinoma. BJU Int (2014) 1.49
The biological response modifier AM3 attenuates the inflammatory cell response and hepatic fibrosis in rats with biliary cirrhosis. Gut (2010) 1.45
Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A (2006) 1.42
Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology (2006) 1.41